Abstract Purpose Factor Xa Inhibitors have emerged as a first-line agent in the management
of non-valvular atrial fibrillation (NVAF), but there is a need for additional data surrounding …

Abstract Background Rivaroxaban (20 mg/15 mg once daily) is an effective and safe
alternative to warfarin for stroke prevention in patients with non-valvular AF (NVAF). Low …

Background The Xarelto Post-Authorization Safety and Effectiveness Study in Japanese
Patients with Atrial Fibrillation (XAPASS) was designed to investigate safety and …

African Americans (AAs) and obese individuals have increased thrombotic risk. This study
evaluated the effectiveness and safety of rivaroxaban versus warfarin in obese, AAs with …

Background There are conflicting data on outcomes in patients with atrial fibrillation treated
with non–vitamin K oral anticoagulants across varying body mass index (BMI). We …

Background Obesity is a risk factor for development of atrial fibrillation (AF). The impact on
stroke outcomes in patients with AF is unknown. We investigated stroke outcomes in normal …

Introduction Due to fixed dosing of direct oral anticoagulants (DOACs), uncertainty exists
about their efficacy in a population of obese/overweight patients. Patients and methods We …

Background Data on the relationship between body mass index (BMI), thromboembolic
events (TEE) and bleeding in patients with atrial fibrillation (AF) are controversial, and further …

The EXPAND Study examined the real-world efficacy and safety of rivaroxaban for the
prevention of stroke and systemic embolism (SE) in Japanese patients with non-valvular …

Background Guidance for dabigatran and rivaroxaban in overweight patients diagnosed
with non-valvular atrial fibrillation (NVAF) is still lacking. Aim Compare the effectiveness and …